DEF 14A: Collegium Pharmaceutical Reports Record Revenue and Share Repurchases in 2023, Outlines 2024 Priorities

Collegium Pharmaceutical achieved record net product revenue and adjusted EBITDA in 2023, increased its cash position, and executed its capital deployment strategy, including share repurchases.

Summary

• Collegium Pharmaceutical had a successful year in 2023, achieving record financial results and advancing its strategic objectives.
• Net product revenue reached $566.8 million, a 22% increase from 2022.
• The company returned $75.0 million to shareholders through share repurchases, with an additional $137.0 million returned to date at an average price of $21.65 per share.
• Collegium paid down $162.5 million in debt and refinanced its convertible debt.
• The FDA granted New Patient Population exclusivity for Nucynta in pediatrics, extending U.S. exclusivity to July 3, 2026, and a pediatric extension was submitted to the FDA.
• The company ended the year with over $310.0 million in cash and marketable securities.
• In 2024, the focus is on operational execution, with expectations to deliver record revenue, adjusted EBITDA, and net income, while continuing to pay down debt and return capital to shareholders.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with record financial results, strategic achievements, and a commitment to returning capital to shareholders. The tone is optimistic and confident.

Positives

• Record net product revenue of $566.8 million, up 22% from 2022.
• Successful renegotiation of Medicare Part D plan for Belbuca, maintaining access and significantly rolling back rebates.
• New Medicare Part D plan secured, representing approximately 1 million covered lives.
• Xtampza ER gross-to-net improved to 59.6%, a decrease of 9.7 percentage points over 2022.
• New Patient Population exclusivity for Nucynta in pediatrics, extending U.S. exclusivity to July 3, 2026.
• Rapid debt repayment of $162.5 million.
• Share repurchase program returned $75.0 million to shareholders.
• Year-end cash and marketable securities balance of over $310.0 million.

Negatives

• The document does not explicitly state any negatives.

Risks

• The document references forward-looking statements that are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from the company's current expectations, including risks described in the company's filings with the SEC.

Future Outlook

Collegium Pharmaceutical expects to deliver on its financial and strategic commitments in 2024 to achieve record revenue, adjusted EBITDA, and net income, while paying down debt and returning capital to shareholders.

Management Comments

• '2023 was a banner year for Collegium Pharmaceutical,' said Joe Ciaffoni, President and Chief Executive Officer.
• He further stated that the company delivered on its key business and financial objectives, including achieving record net product revenue and adjusted EBITDA, increasing its cash position, and executing on its capital deployment strategy.
• Ciaffoni also mentioned that the company is committed to rapidly paying down debt and utilizing its new $150.0 million share repurchase program to continue to return capital to shareholders.

Industry Context

Collegium is positioning itself as a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, focusing on responsible pain management and strategic capital deployment.

Stakeholder Impact

• Shareholders will benefit from the share repurchase program and the company's focus on creating long-term value.
• Employees will benefit from the company's commitment to employee development and culture.
• Patients will benefit from the company's commitment to improving the lives of people living with serious medical conditions.

Next Steps

• The company will continue to focus on operational execution in 2024.
• Collegium will continue to pay down debt and return capital to shareholders through the share repurchase program.
• The company awaits the FDA's decision on the pediatric extension for the Nucynta Franchise.

Key Dates

Keywords

pharmaceutical, revenue, share repurchase, Nucynta, Belbuca, Xtampza ER, exclusivity, debt, EBITDA, FDA, capital deployment